Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25171472 | 0.86 | PDK2 (0.52) | PDK2L3MBTL1DRD2KDM4EALDH1A1 | |
| SCHEMBL21601541 | 0.86 | PDK2 (0.54) | MAPTPDK2L3MBTL1DRD2SMN1; SMN2 | |
| SCHEMBL25581164 | 0.86 | PDK2 (0.47) | MAPTRAB9APDK2DRD2NPC1 | |
| SCHEMBL24344756 | 0.85 | MAPT (0.45) | MAPTRAB9AL3MBTL1CA1CA2 | |
| SCHEMBL7392613 | 0.85 | PDK2 (0.52) | MAPTRAB9APDK2NPC1SMN1; SMN2 | |
| SCHEMBL13186135 | 0.84 | PDK2 (0.52) | MAPTPDK2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL990949 | 0.84 | PDK2 (0.43) | MAPTPDK2DRD2SMN1; SMN2ALDH1A1 | |
| SCHEMBL8257865 | 0.83 | PDK2 (0.54) | RAB9APDK2L3MBTL1NPC1KDM4E | |
| SCHEMBL27174652 | 0.83 | PDK2 (0.54) | PDK2L3MBTL1DRD2KDM4E | |
| SCHEMBL30325180 | 0.83 | MAPT (0.57) | MAPTRAB9ATDP1L3MBTL1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168640-B2 | USP9X inhibitors | ProDeg, LLC (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4433462-A1 | USP9X INHIBITORS | Prodeg, LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240294467-A1 | USP9X Inhibitors | ProDeg, LLC | 2024-09-05 | — | — | US | disclosed |
| US-20230227418-A1 | USP9X INHIBITORS | ProDeg, LLC | 2023-07-20 | — | — | US | disclosed |
| US-20230227418-A1 | USP9X INHIBITORS | ProDeg, LLC | 2023-07-20 | — | — | US | disclosed |
| US-20230227418-A1 | USP9X INHIBITORS | ProDeg, LLC | 2023-07-20 | — | — | US | disclosed |
| US-11691945-B2 | USP9X inhibitors | ProDeg, LLC (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691945-B2 | USP9X inhibitors | ProDeg, LLC (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691945-B2 | USP9X inhibitors | ProDeg, LLC (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023089601-A2 | USP9X INHIBITORS | ProDeg, LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023089601-A2 | USP9X INHIBITORS | ProDeg, LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091464-A1 | USP9X INHIBITORS | ProDeg, LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091464-A1 | USP9X INHIBITORS | ProDeg, LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230150925-A1 | USP9X INHIBITORS | ProDeg, LLC | 2023-05-18 | — | — | US | disclosed |
| US-20230150925-A1 | USP9X INHIBITORS | ProDeg, LLC | 2023-05-18 | — | — | US | disclosed |
| US-20230150925-A1 | USP9X INHIBITORS | ProDeg, LLC | 2023-05-18 | — | — | US | disclosed |
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691945-B2 | USP9X inhibitors | USP9X, USP19, USP39 | MAPT 1926/4885RAB9A 287/4885PDK2 4142/4885 |
| US-20240294467-A1 | USP9X Inhibitors | USP9X, USP19, USP39 | MAPT 1926/4885RAB9A 287/4885PDK2 4142/4885 |
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | MAPT 4631/4885RAB9A 2530/4885PDK2 4635/4885 |
| US-20230150925-A1 | USP9X INHIBITORS | USP9X, USP19, USP39 | MAPT 1926/4885RAB9A 287/4885PDK2 4142/4885 |
| US-12168640-B2 | USP9X inhibitors | USP9X, USP19, USP39 | MAPT 1926/4885RAB9A 287/4885PDK2 4142/4885 |
| US-20230227418-A1 | USP9X INHIBITORS | USP9X, USP19, USP39 | MAPT 1926/4885RAB9A 287/4885PDK2 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.